TNFSF13B and Miyoshi myopathy: BAFF ligand-based CAR-T cells have shown effectiveness in killing cells from various B-cell malignancies, including ALL, mantle cell lymphoma (MCL), and MM cells both in vitro and in vivo [77, 78].